In patients with lung cancer, MIR22HG functions as a cancer suppressor gene and was associated with poor patient survival.45 In addition, low expression of MIR22HG was correlated with hepatocellular carcinoma progression and showed potential as a novel prognostic biomarker and treatment target.46 A relevant study has shown that as a novel biomarker of thyroid cancer, the expression level of MIR22HG is associated with overall survival and prognosis. This evidence concerns the gene MIR22HG and cancer.